Safety
GLP-1 side effects: common symptoms and serious warning signs
GLP-1 treatments often cause gastrointestinal symptoms, but the safety plan must distinguish common effects from symptoms requiring urgent assessment.
Common digestive effects
Nausea, vomiting, diarrhea, constipation, and abdominal symptoms appear in the labels of several GLP-1 medicines. Their frequency varies by product, dose, study, and population. A number from one trial should not be presented as the rate for every drug or compounded preparation.
Symptoms can be more noticeable during escalation. Tell the clinician when they interfere with eating, drinking, sleep, or daily activities. Ask about tolerability before increasing a dose, and do not interpret discomfort as proof that a treatment is working better.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information
Warning signs need assessment
Severe persistent abdominal pain, especially with vomiting, may require evaluation for pancreatitis or other serious disease. Symptoms of a severe allergic reaction, inability to maintain fluid intake, or significant dehydration warrant prompt medical care.
Vomiting and diarrhea can contribute to kidney injury through fluid loss. A clinic should provide a clear route to clinical assessment rather than treating every symptom as a customer-service question. Use emergency services for severe allergic symptoms or other emergencies.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information
Low blood sugar and medicine combinations
Glucose-dependent effects do not eliminate hypoglycemia risk. Insulin or sulfonylureas used alongside these treatments can increase that risk, and the prescriber may adjust them. Do not independently change diabetes medicines based on one reading.
Ask what symptoms and glucose results should trigger the clinician's hypoglycemia plan. If you have eye disease related to diabetes, discuss monitoring, particularly when glucose control changes quickly.
Sources: Ozempic prescribing information · Mounjaro prescribing information
A usable follow-up plan
Keep the product, formulation, dose, escalation date, symptom pattern, and medicine list available. Ask who handles urgent symptoms, when follow-up is scheduled, and what to do if treatment is interrupted.
Tell the anesthesia team about treatment before planned surgery or sedation. Review pregnancy plans and product-specific contraception precautions. Compounded treatment requires its own formulation assessment and does not inherit approved-product safety evidence.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information · Foundayo prescribing information · FDA concerns with unapproved GLP-1 drugs used for weight loss
Sort symptoms by impact, persistence, and associated signs
A mild symptom that does not interfere with intake has a different practical meaning from repeated vomiting or pain that prevents normal activities. Record onset, relation to dose changes, duration, and accompanying symptoms. This helps the clinician assess tolerability and other possible causes. The fact that nausea or diarrhea appears in a label does not mean every episode can safely be ignored.
Persistent severe abdominal pain, particularly with vomiting, needs assessment because pancreatitis is among the important warnings. Symptoms suggesting an allergic reaction, such as trouble breathing or swelling, need urgent care. Vomiting and diarrhea that prevent hydration also deserve prompt attention. A review site cannot determine the cause from a symptom list, and absence of one classic sign does not prove that a serious problem is excluded.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information · Mounjaro prescribing information · Foundayo prescribing information
Other medicines can change the safety picture
GLP-1-related treatments may be combined with insulin or sulfonylureas in diabetes care, increasing hypoglycemia risk. The prescriber may need to adjust those treatments and monitoring. A person should not stop insulin based on appetite reduction or assume that glucose-dependent action makes low glucose impossible. Bring the full regimen to review, including newly started medicines and supplements.
Product-specific interactions also matter. Tirzepatide and Foundayo have oral contraception precautions with different protection periods. Foundayo has additional metabolism and transport interactions that can restrict its maximum dose. Oral semaglutide has administration timing that affects other morning medicines. A safety review should identify the actual product and route rather than apply one class-wide list to every prescription or a different compounded formulation.
Sources: Mounjaro prescribing information · Zepbound prescribing information · Foundayo prescribing information · Rybelsus and Ozempic tablets prescribing information
What a useful follow-up should resolve
Discuss whether you can maintain food and fluid intake, whether symptoms began after an increase, and whether another illness or medicine could contribute. The clinician can assess the treatment plan and need for investigation, while a dietitian can help with tolerated nourishment. The nutrition advisory supports individualized symptom and nutrition management rather than a universal supplement or meal prescription.
Before the next refill, confirm the dose, follow-up date, and clinical contact route. Severe symptoms should not wait for that date. If treatment is paused, ask for a product-specific restart plan; a former maintenance dose may not remain tolerable after a long gap. Suspected adverse events or quality problems can be reported through FDA MedWatch. Compounded products also require review of formula, concentration, and measurement when a dosing error is possible.
Sources: Joint advisory: nutritional priorities to support GLP-1 therapy for obesity · Wegovy prescribing information, including tablets and Wegovy HD · FDA concerns with unapproved GLP-1 drugs used for weight loss
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.
- Wegovy prescribing information, including tablets and Wegovy HD
- Ozempic prescribing information
- Zepbound prescribing information
- Mounjaro prescribing information
- Foundayo prescribing information
- FDA concerns with unapproved GLP-1 drugs used for weight loss
- Rybelsus and Ozempic tablets prescribing information
- Joint advisory: nutritional priorities to support GLP-1 therapy for obesity